Jubilant DraxImage receives approval for new pulmonary indications from the U.S. Food and Drug Administration for DRAXIMAGE® DTPA Montreal, QC, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Jubilant DraxImage Inc. (“DraxImage”), a Jubilant Pharma wholly-owned subsidiary, is pleased to announce approval of new pulmonary indications for...

Jubilant DraxImage receives approval for 12-Hour shelf-life extension from the U.S. Food and Drug Administration for DRAXIMAGE® MAA Montreal, QC, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Jubilant DraxImage Inc. (“DraxImage”), a wholly-owned subsidiary of Jubilant Pharma, is pleased to announce the U.S. Food and Drug Administration...

Jubilant DraxImage receives approval from Health Canada for the RUBY Elution System™ (RbES) and proprietary RUBY™ Consumable Accessories Montreal, QC, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Jubilant DraxImage Inc. (“DraxImage”), a Jubilant Pharma whollyowned subsidiary, is pleased to announce it has received approval from Health Canada...